Cognitive Peptides Guide
If you're reading this, there's a decent chance you're a professional in your 30s or 40s who's noticed something you can't quite explain: the sharpness isn't there the way it used to be. Maybe it's brain fog after lunch. Maybe it's difficulty sustaining focus through a long afternoon. Maybe it's a general sense that your cognitive edge has dulled, and no amount of coffee, sleep optimization, or productivity hacks seems to fully fix it.
And then someone \u2014 a podcast guest, a Reddit thread, a gym buddy \u2014 mentioned peptides for cognitive function. Semax for focus. Selank for anxiety and clarity. Dihexa as some kind of super-compound that's “millions of times more potent than BDNF.”
So you went looking for a clear, honest breakdown. And you probably found the same thing we did: vendor-funded content that makes every compound sound like a miracle, biohacker forums full of anecdote but short on data, and almost nothing written for someone who wants the real evidence picture before making a decision.
This guide fills that gap. Below you'll find a side-by-side comparison and brief summaries of each compound. For the full mechanism, research, protocol, and risks, follow the link to each individual profile. New to peptides generally? Start with Peptides 101.
The Cognitive Peptide Landscape at a Glance
Before diving into individual compounds, here's an honest snapshot of where the evidence stands across the category:
| Compound | Mechanism | Human Data | Evidence | Regulatory |
|---|---|---|---|---|
| Semax | ACTH derivative. Modulates dopamine/serotonin, upregulates BDNF. | Russian clinical use since 2011. Human studies on attention, BDNF, stroke recovery. Most published in Russian. | T2: Emerging Evidence | Was Category 2. Expected to return to Category 1 (not yet formalized). |
| Selank | Tuftsin derivative. Modulates GABA without sedation; anxiolytic + cognitive effects. | Stage III trials completed in Russia for anxiety. 2020 fMRI study in 52 healthy participants. | T2: Emerging Evidence | PCAC-referred September 2024. Expected among ~14 peptides returning to Category 1. |
| Dihexa | Synthetic hexapeptide. HGF/c-Met activation for synaptogenesis. | Zero human studies. Foundational paper retracted; clinical derivative failed Phase 2/3. | T3: Early / Anecdotal | Category 2 — expected Category 1. Not PCAC-referred. Significant red flags. |
| PE-22-28 | Spadin analog. TREK-1 channel inhibition for mood/cognition. | No human studies. Animal data only. | T3: Early / Anecdotal | Category 2 — expected Category 1. Not PCAC-referred. |
The honest headline
Semax and Selank have the most evidence and the longest track record \u2014 approved and used in Russia since the early 2010s, with some human data. Dihexa gets the most hype but has the weakest evidence base, and its foundational research has been seriously compromised. PE-22-28 and similar emerging compounds are almost entirely pre-clinical. If you're considering a cognitive peptide, Semax and Selank are where the evidence-to-risk ratio is most favorable. Everything else requires a substantially higher tolerance for uncertainty.
Regulatory Note (April 2026)
The regulatory landscape for cognitive peptides is shifting. In February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 Category 2 peptides would return to Category 1 status, restoring compounding eligibility. Both Semax and Selank are expected to be among them. However, as of this writing, no formal FDA policy change has been issued. The PCAC charter expires April 25, 2026, and whether it will be renewed is an open question. We are tracking this actively. Check our Regulatory Tracker for the latest status. Do not purchase peptides from unregulated sources based on announcements alone. Wait for formal FDA guidance and work with a licensed provider.
The Compounds
Each compound has its own full profile with mechanism, research, protocol, risks, and provider questions. Click through for the complete picture.
Semax
T2: Emerging EvidenceAn ACTH-derived nasal peptide approved as a pharmaceutical in Russia since 2011. Modulates dopamine/serotonin and upregulates BDNF. The strongest evidence-to-risk ratio for focus and cognitive enhancement in this category, with the caveat that most research is in Russian. Read the full Semax profile →
Selank
T2: Emerging EvidenceA tuftsin-derived nasal peptide that modulates GABA without sedation, tolerance, or dependency. Stage III Russian trials for anxiety; PCAC-referred in September 2024 \u2014 further along in U.S. reclassification than Semax. Frequently paired with Semax. Read the full Selank profile →
Dihexa
T3: Early / AnecdotalThe most hyped and least proven cognitive peptide. Foundational research has been retracted, no human trials exist, and the “millions of times more potent than BDNF” claim traces back to compromised work. We cannot recommend it. Read the full Dihexa profile →
PE-22-28
T3: Early / AnecdotalA spadin analog targeting TREK-1 channels for mood and cognition. Almost entirely preclinical, with minimal published data. Included for completeness, but Semax and Selank are stronger starting points. Read the full PE-22-28 profile →
PeptideClarity Position on Cognitive Peptides
Cognitive peptides are the most exciting and most overpromised category in the peptide space. The gap between what the community believes and what the evidence shows is wider here than in any other category.
Semax and Selank are the real starting points. They have the most human data, the longest clinical track record (Russian, but real), complementary mechanisms, and manageable risk profiles. They're not proven by Western clinical trial standards, but they're far beyond the anecdotal stage.
Dihexa is a cautionary tale. Dramatic preclinical claims, retracted foundational research, a failed clinical trial, an unresolved cancer risk, and zero human safety data. The “millions of times more potent” claim may not survive scrutiny, and the fact that most peptide content doesn't mention the retraction should tell you something about the information landscape.
PE-22-28 is included for completeness. The evidence does not currently support confident recommendations.
If you're experiencing cognitive decline that's affecting your work and life, the first step isn't a peptide. It's a thorough evaluation by a provider who will check for simpler causes. If those are ruled out or addressed, and you want to explore peptides, Semax and Selank represent the most evidence-supported options. Work with a provider. Track your response. Set decision points. And be honest with yourself about what's working and what isn't.
Signal through the noise.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.